Immunovia (BATS-CHIXE:IMMNOS) - Cotización, noticias y análisis

Resumen de acción IMMNOS

A diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden.

IMMNOS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 94.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 76.7%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares (SEK949K)

Acciones altamente ilíquidas

Tiene menos de 1 año de cash runway

No tiene una capitalización de mercado significativa (SEK552M)

Competidores de Immunovia AB (publ)

ANGLE

AIM:AGL

UK£50.1m

NetScientific

AIM:NSCI

UK£16.2m

Belluscura

AIM:BELL

UK£26.0m

Creo Medical Group

AIM:CREO

UK£122.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Immunovia
Historical stock prices
Current Share Price	kr34.30
52 Week High	kr63.05
52 Week Low	kr30.28
Beta	1.41
1 Month Change	0%
3 Month Change	-4.08%
1 Year Change	-44.68%
3 Year Change	-79.87%
5 Year Change	n/a
Change since IPO	-77.15%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	IMMNOS	GB Medical Equipment	Mercado GB
7D	0%	-3.2%	-1.2%
1Y	-44.7%	-9.2%	7.0%

Rentabilidad vs. Industria: IMMNOS obtuvo unos resultados inferiores a los del sector UK Medical Equipment , que el año pasado arrojó un rendimiento del -10.7%.

Rentabilidad vs. Mercado: IMMNOS obtuvo unos resultados inferiores a los del mercado UK, que fue del -1.8% el año pasado.

Volatilidad de los precios

Is IMMNOS's price volatile compared to industry and market?
IMMNOS volatility
IMMNOS Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.3%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.0%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: IMMNOS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de IMMNOS en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2007	64	Philipp Mathieu	www.immunovia.com

Resumen de fundamentos de Immunovia AB (publ)

¿Cómo se comparan los beneficios e ingresos de Immunovia con su capitalización de mercado?
Estadísticas fundamentales de IMMNOS
Capitalización bursátil	kr551.76m
Beneficios(TTM)	-kr147.90m
Ingresos (TTM)	kr949.00k

581.4x

Ratio precio-ventas (PS)

-3.7x

Ratio precio-beneficio (PE)

¿Está IMMNOS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IMMNOS
Ingresos	kr949.00k
Coste de los ingresos	kr4.15m
Beneficio bruto	-kr3.20m
Otros gastos	kr144.70m
Beneficios	-kr147.90m

Últimos beneficios comunicados

Sep 30, 2022

Próxima fecha de beneficios

Feb 09, 2023

Beneficios por acción (BPA)	-6.54
Margen bruto	-336.78%
Margen de beneficio neto	-15,584.62%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IMMNOS a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción IMMNOS

Recompensas

Análisis de riesgos

Competidores de Immunovia AB (publ)

AIM:AGL

UK£50.1m

AIM:NSCI

UK£16.2m

AIM:BELL

UK£26.0m

AIM:CREO

UK£122.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Recent updates

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently bought kr186k worth of stock

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Iimmunovia AB (Publ) Publishes Data Sets on the Optimization Study and Commercial Test Model Study

Full year 2020 earnings released: kr6.84 loss per share (vs kr5.85 loss in FY 2019)

Revenue in line with expectations

Immunovia AB (publ) to Report Q1, 2021 Results on Apr 28, 2021

Immunovia's PanFAM Prospective Study Gathers over 3000 Familial Hereditary Pancreatic Cancer Risk Samples and Will Be Analysed in the Second Half of 2021

Immunovia AB Announces Results from Study in Their Development Pipeline

New 90-day low: kr111

Director recently bought kr144k worth of stock

New 90-day low: kr122

Immunovia AB (Publ) Announces Appointment of Members of Nomination Committee

Immunovia AB (publ) Announces Management Changes

Immunovia AB (Publ) Announces Completion of Analysis from the Immray Pancan-D Verification Study

Immunovia Announces Positive Results from the Immray Pancan-D Verification Study

Immunovia AB (Publ) Appoints Mats Grahn as New Member of the Board of Directors

Immunovia Announces CEO Transition, Effective November 1, 2020